![Robert Ghenchev](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Ghenchev
Directeur/Membre du Conseil chez
EXSCIENTIA PLC
Profil
Robert Ghenchev is currently Director at Mission Bio, Inc., Exscientia AI Ltd., Exscientia Ltd., Mightyowl, Inc., and Quanta Dialysis Technologies LLC.
Mr. Ghenchev is also Head-Growth Equity at Novo Holdings Equity US, Inc. since 2025.
Former roles include Director at Tempus AI, Inc., Non-Executive Director at Oxford Biomedica Plc from 2019 to 2025, Senior Vice President at Moelis & Company UK LLP from 2010 to 2018, and Managing Partner at Novo Growth from 2018 to 2025.
Education includes a graduate degree from the University of Oxford in 2007 and an undergraduate degree from McGill University in 2006.
Postes actifs de Robert Ghenchev
| Sociétés | Poste | Début |
|---|---|---|
| EXSCIENTIA PLC | Directeur/Membre du Conseil | 01/05/2020 |
Exscientia AI Ltd.
 Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Provides AI and machine learning techniques based drug discovery services | Directeur/Membre du Conseil | 01/05/2020 |
Mission Bio, Inc.
 Mission Bio, Inc. BiotechnologyHealth Technology Develops single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development | Directeur/Membre du Conseil | - |
Mightyowl, Inc. | Directeur/Membre du Conseil | - |
Novo Holdings Equity Us, Inc.
 Novo Holdings Equity Us, Inc. Financial ConglomeratesFinance Operates as holding company that provides investment services for life science companies | Corporate Officer/Principal | 21/03/2025 |
Quanta Dialysis Technologies, Inc.
 Quanta Dialysis Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Quanta Dialysis Technologies, Inc. is an American medical technology company focused on transforming kidney care through its dialysis system. The company is located in the US. The platform supports all major hemodialysis modalities, including intermittent hemodialysis, sustained low efficiency dialysis, continuous renal replacement therapy, and home hemodialysis, delivered from a single, compact, portable device without the need for dialysate bags. The system uses disposable cartridge-based dialysate technology that eliminates daily rinses and harsh chemical disinfections, requiring only a once-weekly hot rinse, and offers flexible prescription options with easy training and minimal maintenance. It is designed for use in clinics, ICUs, post-acute care, and home settings, and features a lightweight, space-saving design with an intuitive touchscreen interface. The Quanta cart accessory enhances mobility and modularity for bedside treatments and is compatible with portable reverse osmosis units. The company also provides a digital health platform, CareLinq, for real-time machine connectivity, operational excellence, fleet management, and staff e-learning. Quanta holds worldwide patents and registered trademarks protecting its technology and branding, and its technology is supported by published clinical research and validated through clinical trials. | Directeur/Membre du Conseil | - |
Anciens postes connus de Robert Ghenchev
| Sociétés | Poste | Fin |
|---|---|---|
Novo Growth
 Novo Growth Investment ManagersFinance Novo Growth invests in companies located across the globe. The firm focuses on companies operating in the fields of life science, technology, industrial biotechnology, complex manufacturing and supply chain sectors and industries. It participates in growth transactions with an investment size of USD 30 - 100 million. | Private Equity Investor | 01/11/2025 |
| OXFORD BIOMEDICA PLC | Directeur/Membre du Conseil | 20/10/2025 |
Moelis & Co. (UK) LLP
 Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | 01/01/2018 |
| ░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Robert Ghenchev
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
91
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Oxford Biomedica Plc
 Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Moelis & Co. (UK) LLP
Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Provides brokerage services | Finance |
Tempus AI, Inc.
 Tempus AI, Inc. Packaged SoftwareTechnology Services Develops clinical & molecular data platform for healthcare | Technology Services |
Mission Bio, Inc.
Mission Bio, Inc. BiotechnologyHealth Technology Develops single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development | Health Technology |
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Provides AI and machine learning techniques based drug discovery services | Health Technology |
Novo Growth
Novo Growth Investment ManagersFinance Novo Growth invests in companies located across the globe. The firm focuses on companies operating in the fields of life science, technology, industrial biotechnology, complex manufacturing and supply chain sectors and industries. It participates in growth transactions with an investment size of USD 30 - 100 million. | Finance |
Exscientia Plc
 Exscientia Plc Packaged SoftwareTechnology Services Function as an investment holding company whose subsidiaries provides artificial intelligence and machine learning services | Technology Services |
Mightyowl, Inc. | |
Novo Holdings Equity Us, Inc.
Novo Holdings Equity Us, Inc. Financial ConglomeratesFinance Operates as holding company that provides investment services for life science companies | Finance |
Quanta Dialysis Technologies, Inc.
Quanta Dialysis Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Quanta Dialysis Technologies, Inc. is an American medical technology company focused on transforming kidney care through its dialysis system. The company is located in the US. The platform supports all major hemodialysis modalities, including intermittent hemodialysis, sustained low efficiency dialysis, continuous renal replacement therapy, and home hemodialysis, delivered from a single, compact, portable device without the need for dialysate bags. The system uses disposable cartridge-based dialysate technology that eliminates daily rinses and harsh chemical disinfections, requiring only a once-weekly hot rinse, and offers flexible prescription options with easy training and minimal maintenance. It is designed for use in clinics, ICUs, post-acute care, and home settings, and features a lightweight, space-saving design with an intuitive touchscreen interface. The Quanta cart accessory enhances mobility and modularity for bedside treatments and is compatible with portable reverse osmosis units. The company also provides a digital health platform, CareLinq, for real-time machine connectivity, operational excellence, fleet management, and staff e-learning. Quanta holds worldwide patents and registered trademarks protecting its technology and branding, and its technology is supported by published clinical research and validated through clinical trials. | Electronic Technology |
Choisissez Zonebourse 
